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Aims Anticancer therapies have extended the lives of millions of patients with malignancies, but for some this benefit is tem-
pered by adverse cardiovascular (CV) effects. Cardiotoxicity may occur early or late after treatment initiation or termin-
ation. The extent of this cardiotoxicity is variable, depending on the type of drug used, combination with other drugs,
mediastinal radiotherapy, the presence of CV risk factors, and comorbidities. A recent position paper from the European




The current document is focused on the basis of the Cardio-Oncology (C-O) Services, presenting their rationale,
organization, and implementation. C-O Services address the spectrum of prevention, detection, monitoring, and
treatment of cancer patients at risk of cardiotoxicity and/or with concomitant CV diseases. These services require a
multidisciplinary approach, with the aims of promoting CV health and facilitating the most effective cancer therapy.
...................................................................................................................................................................................................
Conclusion The expected growing volume of patients with cancer at risk of developing/worsening CV disease, the advent of new
technological opportunities to refine diagnosis, and the necessity of early recognition of cancer therapy-related toxicity
mandate an integrative multidisciplinary approach and care in a specialized environment. This document from the ESC
Cardio-Oncology council proposes the grounds for creating C-O Services in Europe based on expert opinion.
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Cancer is currently the second most common cause of death in
Europe after cardiovascular (CV) diseases. With the expected 23.6
million new cancer cases worldwide each year by 20301 and the rap-
idly growing number of patients surviving cancer, often in the setting
of advanced age, new or pre-existing CV disease and risk factors, the
management of these patients has become the concern of experts in
Cardio-Oncology (C-O).2 For many years, cardiologists have colla-
borated with cancer specialists to assist them in the management of
CV comorbidities and provide guidance on optimal CV therapy.
Currently, the role of the cardiologist has expanded from treating
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..acute and chronic effects of cancer therapies to focus on early pre-
ventive strategies promoting a multidisciplinary patient-centred ap-
proach in a dedicated environment, namely the C-O Clinic.3,4 A
recent position paper of the European Society of Cardiology (ESC)
has reported the most common CV complications related to anti-
cancer treatments and has set the optimal management of these
patients.5 Cardio-Oncology is an area in expansion in Europe.
However, there are, in our knowledge, very few data about C-O
Services with a great confusion of specific roles and organization. In
the present document from the ESC Cardio-Oncology council, we
focused on the description of the basis of C-O Services, by approach-
ing its rationale, organization, and implementation.
Cardio-Oncology Services
Cardio-Oncology Services should be conceived as an alliance of dedi-
cated professionals to provide multidisciplinary specialized evaluation
and consistent, continuous, coordinated, and cost-effective care dur-
ing the cancer process.6,7 The knowledge of the cardiac side effects
of anticancer agents and radiation therapy, balanced with the know-
ledge regarding the natural history of the malignancy and the benefits
of oncologic treatments offers the greatest opportunity for long-
term disease-free survival. Table 1 summarizes C-O Services goals.7
The degree of organization of a C-O Service has a direct impact
on both the quality of patient care and outcome provided. The C-O
Team typically includes core members (medical and radiation oncol-
ogists, haematologists, cardiologists, and specialized nurses) and sup-
port members [patients’ general practitioners (GPs), cardiac
surgeons, cardiologists specialized in other domains, pathologists,
radiologists, palliative care team, clinical laboratory specialists, hos-
pital pharmacists, psychologists, social workers, and data managers].
While the composition of a C-O Team may vary in accordance with
hospital size and organization, it is essential to agree on local proto-
cols, as well as clinical and research quality standards that promote
the effective use of available resources8 (Figure 1).
Objectives of Cardio-Oncology
Teams
The objectives of C-O Teams include (i) prior to the cancer therapy,
the identification of potential risk factors leading to cancer
treatment-related CV complications, the optimization of CV health
to ensure safe cancer surgery and allow optimal local and systemic
anticancer therapy and when optimization of CV health cannot be
achieved, interdisciplinary discussion to ensure most efficacious can-
cer treatment without substantial CV harm; (ii) during cancer treat-
ment, early identification, and appropriate treatment of CV
complications and interdisciplinary discussion to make clinical
decisions in patients experiencing CV side effects; (iii) after cancer
treatment, optimization of preventive strategies, screening for late-
onset complications as well as re-assessment of risk for CV complica-
tions in patients in need of treatment for secondary cancers5,9,10
(Figure 2).
• The prevention of CV complications in cancer patients requires a
comprehensive evaluation of CV risk profile and physical exam,
including evidence of manifest arteriosclerotic disease, blood
pressure, and cardiac function before starting any kind of poten-
tially cardiotoxic anticancer therapy.5,10 This screening should
be performed by cardiologists in order to select the most ap-
propriate therapy for the individual patient. This is mainly im-
portant in the adjuvant setting or for oncologic malignancies
with good prognosis where patients are already potentially
cured or survive for several years and a high risk of long-term
major side effects is not acceptable. Accordingly, cardiologists
will discuss with oncologists the expected CV risk of the
selected therapy, to define the optimal frequency of CV moni-
toring. Interactions of cancer drugs with pre-existing cardiac
medications (e.g. anticoagulation, drugs metabolized via the
cytochrome CYA3A4. . .) should also be considered prior to
treatment in all patients.11
• The optimization of CV health for cardiac patients and the facilita-
tion of anticancer treatment in patients with CV complications are
both natural consequences of this approach. This also includes
specific recommendations on appropriate use of CV medica-
tions such as antiplatelet and anticoagulant therapeutics during
cancer treatment.5,12,13
• The early identification and treatment of CV complications are two
core missions of a C-O Team. The oncologists should monitor
carefully symptoms/signs during anticancer therapy in order to
differentiate those related to cancer from others, directly due
to cardiac involvement. The most frequent dilemma is the bal-
ance of continuing vs. interrupting anticancer therapy, and
whether the cancer or CV disease is the greater threat to the
patient’s survival.5 Applying the best of modern cardiology care,
with engagement of subspecialties promptly, may be a pre-
requisite to allow or continue cardiotoxic therapy, or minimiz-
ing interruptions of important cancer treatments.6
• The surveillance for late CV complications in cancer survivors is
probably the most difficult to translate into practice because
detrimental effects exerted by both systemic anticancer drugs
Terminology
• Cardio-Oncology Team (C-O Team) is a multidisciplinary team (MDT) of dedicated professionals to provide specialized cardiovascular
evaluation and care in all stages of the cancer process.
• Cardio-Oncology Clinic (C-O Clinic) is any organization with a C-O Team and the facilities to take care of ambulatory cancer patients in
a coordinated manner. C-O Clinic is supported by the cardiology department to perform additional tests (i.e. invasive) and when a pa-
tient is admitted at hospital.
• Cardio-Oncology Services (C-O Services) in tertiary/university health-centres coordinate C-O Clinics around their catchment area,
take care of inpatients cardiovascular complications and coordinate research and educational areas in cardio-oncology.
• Oncologists or cancer specialists: These terms refer to either specialists in medical oncology, radiation oncology, and haematology.
























































and radiotherapy can appear years to decades after receiving
these therapies.1–3 The correct long-term strategy for cardio-
toxicity monitoring requires not only the existence of a C-O
Team but also the ability to organize a long-term surveillance
programme, focused on patients’ education and treatment ad-
herence, in collaboration with GPs and specialized nurses.
Furthermore, care-takers should be aware that patients after
cancer therapy frequently experience atypical CV symptoms—
for example silent ischaemia after mediastinal radiation.9
Structure and organization
Models of Cardio-Oncology Services
Various models of C-O Services exist depending upon the structures
of the local health service, hospitals, and their specialization
(Table 2).3–5,14,15 In large tertiary hospitals and university hospitals
with cardiology and oncology services, C-O Services can exist within
cardiology departments with direct oncology involvement. As services
grow, C-O Services may have inpatient dedicated team and outpatient
C-O clinics dedicated to specific cancer groups (e.g. breast cancer,
lymphoma, long-term survivors) and both cardiology and oncology
specialists can deliver the service in the same clinical environment and
location. In specialist oncology hospitals two models of service exist
depending on both clinical (necessity) and practical (geographical, con-
tractual) issues. Some centres have set up ‘in house’ cardiology serv-
ices. Alternatively, specialized oncology centres have partnered with
specialist cardiac centres to deliver the C-O Services for their oncology
patients. In either case the provision of a MDT meeting is fundamental
for the review of complex patients and periodic review of the quality
and provision of the C-O Services. Another important variable is the
scope of the C-O Services. C-O Clinics deliver CV care for ambulatory
patients either using an outpatient clinic model or a dedicated day-case
assessment model. In smaller district hospitals C-O Clinics work with a
standard outpatient clinic model, with a limited scope in the range of
service offered (e.g. symptomatic management of common cardiac
symptoms, surveillance imaging for specific treatments follow-up ap-
pointment to review the results, and guide treatment after a C-O
Team discussion). Smaller C-O clinics should ideally be connected in a
strategic partnership to larger regional C-O Services, so complex cases
can be referred as inpatient or outpatient when required.
In large centres, specific C-O consultations are generally based on
a day-case model tailored to the individual patient’s need and to the
type of anticancer therapy performed. C-O consultation provides
clinical review, appropriate non-invasive cardiac investigations [car-
diac biomarkers, electrocardiogram (ECG), standard and advanced
echocardiography, and stress test] and MDT discussion on the same
day, thereby limiting the number of additional visits, and treatment
delays or interruptions (Table 3). In tertiary centres, the full range of
advanced cardiac imaging (cardiac magnetic resonance and advanced
echocardiography, coronary computed tomography angiography)
and interventional and electrophysiological treatments, can be deliv-
ered in collaboration with the cardiology department.9,16,17 C-O
Team can also provide e-consults for streamline fast patients’ care
pathways in high-risk populations (Table 3). Follow-up clinics can also
be general or specialized, with beyond biological evaluation and ECG,
advanced echocardiography support for monitoring patients requir-
ing heart failure surveillance. Further in-hospital support for oncology
patients who develop acute or new cardiac symptoms/side effects
during admission must also be provided. These larger C-O Services
also provide the infrastructure for offering education and training, re-




Cardio-Oncology consultations are directed at patients at high risk of
CV complications related to anticancer treatment5: (i) patients
receiving potentially cardiotoxic treatment; (ii) patients prior to can-
cer surgery, if they have previous CV diseases or those who are
expected to receive additional cancer treatment; (iii) patients who
...............................................................................................
Table 1 Goals of the Cardio-Oncology Services
Unification of the cancer care process
• Effective communication and coordination among professionals
involved in cancer patients care to minimize unnecessary costs
• Development and adherence to local clinical protocols to reduce
individual decisions
• Optimize acute and long-term cardiovascular health for patients
who need potentially cardiotoxic drugs
• Prevention, early diagnosis, and treatment of cancer therapy-
related cardiovascular complications
• Reduce interruptions of anticancer drugs
• Coordination of continuous medical education, medical training,
and clinical research in cardio-oncology
• Health care quality control for clinical and research practice






















































..develop CV symptoms during oncological treatments; (iv) patients
receiving cancer treatment who develop asymptomatic newly
reduced cardiac function; (v) patients with prior childhood cancer
treatment before planning pregnancy, or developing CV symptoms
during pregnancy (Table 3, Figure 2).
Roles and responsibilities
Oncologists should be in charge for the selection of patients to be
referred to the cardiology clinic. The main role of the cardiologists is
to facilitate cancer treatments providing clear diagnostic tests, early
interventions in case of clinical and subclinical toxicity, and assisting
clinical decision-making regarding continuation, modification, or
interruption of the cancer therapy.
Responsibility for decision-making, provision of cardiac surveil-
lance, and follow-up should be agreed in a MDT discussion to ensure
that optimal care is provided, e.g. if routine cardiac surveillance is pro-
vided using biomarkers by an oncologist and heart failure is suspected,
further treatment and surveillance may be offered by the cardiologist.
In order to speed up this process, it is recommended to agree on
clinical protocols and referral pathways adapted to the centre
resources and focus on complex cases during C-O Team discussions.
In tertiary centres, dedicated specialist nurses can coordinate all diag-
nostic tests, cardiology visits, and e-consultations.
Pathways for cancer patients in Cardio-
Oncology Services
Care tracks or pathways, adapted to different therapeutic schemes
and previous CV conditions, should be developed among the differ-
ent health care providers (medical oncologists, radiation oncologists,
haematologists, cardiologists, radiologists, cancer surgeons, and
anaesthesiologists) to minimize delays in cardiac examinations and
treatment decisions. Education of all teams within the C-O Services
in this process is mandatory. Audit of the timings from referral initi-
ation, receipt and then patient review is encouraged to identify where
delays can be minimized or prevented. A new cancer diagnosis or
new CV symptoms in this population must activate the process for
referring patients to the C-O Clinic.
Requirements of specialized Cardio-
Oncology Clinics
Cardio-Oncology Clinic requires a multidisciplinary C-O Team to ad-
dress the complex clinical and psychological impact of both cancer
and cardiac diseases.14 Cardiologists with a special interest in C-O,
heart failure, and advanced cardiac imaging usually lead the service,
with support from cardiologists with other specialist expertise (elec-
trophysiology, intervention, grown-up congenital heart disease, vas-
cular disease, hypertension, and pulmonary hypertension). Regular
multidisciplinary C-O Team meetings provide a suitable structure to
review complex patients.
Efficient secretarial and administrative support is required to en-
sure patients are scheduled in the C-O Clinic, as well as to organize
pathways for appropriate cardiac evaluations and to integrate results
for MDT discussion.
Moreover, organized software if available can be implemented to
have a complete database of patients and an automatic tool remind-
ing what cancer therapy the patient received, what are and the timing
of eventual exams for the follow-up of the patient and an alert to the
C-O Service health personnel, to the GP and to the patient of the
scheduled activity, to avoid escapes from the follow-up program.
This software may facilitate implementation of CV monitoring in
patients involved in oncology trials. An example of database is pro-
vided in Table 4.
Collection of patient experience via questionnaires or surveys is
encouraged and helpful to guide service development, identify weak-
nesses and inefficiencies, and provide patient-reported outcome
measures as one metric of quality. Collection of clinical data in local
registries and, when relevant, in national and international registries is
encouraged to grow experience and to identify the prevalence and
Figure 2 Eligible patients for Cardio-Oncology Consultation and Cancer patients’ pathways. CV, cardiovascular; CVRF, cardiovascular risk factors;
ECG, electrocardiogram; Rx, cancer therapy. aAnthracyclines, anti-HER2 therapies, VEGF or BCR-ABL targeted TKIs, proteosomal inhibitors, and
thoracic radiotherapy. TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor.












nature of cardiotoxicity from cancer therapies, and the demographics
of patients referred to a C-O Service.
Governance and audit
Regular C-O governance meetings are encouraged with contribution
and feedback from all members of the C-O Team. Review of activity,
referral sources, patient feedback, timings, and rapidity of service de-
livery (e.g. time from referral to assessment) are important.14 The im-
pact of the service can be measured using audit (e.g. number of
oncology patients who restart and complete oncology protocols fol-
lowing interruption of oncology care for cardiotoxicity, and number
of high-risk patients who complete oncology treatment without
interruptions for cardiotoxicity).
....................................................................................................................................................................................................................
Table 2 Organization of Cardio-Oncology Services
Requirements General/district hospitals Tertiary hospitals Additional at selected centres
Patients <10 patients /week a > 10 patients/week a > 20 patients/week a
Structures of the hospital Cardiology section/department
Oncology section/department
General intensive care unit
Cardiology department




Intensive cardiac care unit
Cardiac transplant program
Multidisciplinary teams
• Organization Basic Cardio-Oncology Team
(core members) or a dedi-
cated consultant cardiologist
In Oncology Centres: “in
house” basic cardiology
services
Connected with primary care
physicians
Cardio-Oncology Team (core
members þ allied members)
Connected with primary care
physicians and general/district
hospitals
Cardio-Oncology Team (core mem-




Facilities for research protocols
Connected with primary care physi-
cians, general/district hospitals and
tertiary hospitals
• Dedicated outpatient C-O
clinic
Recommended Available Available ( þ e-cardio-oncology
consult)
• 24/7 h Recommended Available for acute inpatient
problems










Health care professionals training
programs
Health care professionals training























Smaller services should be con-




Available þ Cardiac transplantation
Data review
• Internal audit processes









aNumbers are suggested by common experience of an expert consensus discussion.
CMR, cardiac magnetic resonance; PET_CT, positron emission tomography–computed tomography.
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Table 3 Objectives, resources, and needs for Cardio-Oncology Consultation and e-consultation
Cardio-oncology consultation e-Cardio-oncology consultation
Objectives Careful history and physical examination of cancer patients with
a moderate to high risk of developing cardiotoxicity or previ-
ous heart diseases
• Before cancer treatment (anticancer drugs, radiotherapy
and cancer surgery): optimize cardiovascular treatment,
review drug-drug interactions, stablish follow-up needs
• During cancer treatment: monitoring of cancer treat-
ments. Early diagnosis and treatment of CV complications
• Long-term survivors surveillance
From cancer specialists to cardiologists
• Optimization of cardiovascular risk factors control in
asymptomatic patients without structural heart disease
• Advice regarding drug-drug interactions
• Advice regarding referral to centres with greater special-
ization on cardio-oncology
From GPs’ to cardiologists
• Advice regarding referral to cardio-oncology clinic
Cardiovascular monitoring before planning pregnancy in long-
term survivors
From patients to specialized nurses (e-nurse cardio-oncology
consult)
• Tight controls of some patients after C-O consultation
focused on diet advices, exercise recommendations, new
symptoms, treatment tolerance, treatment adherence,
blood pressure, or glucose control
Cardiovascular monitoring of patients involved in oncologic
clinical trials
Human Cardio-oncologist Cardio-oncologist
Resources Specialized nurse Specialized nurse
Technical resources Sphygmomanometer Digitalized medical records
ECG including QTc measurement
Transthoracic echocardiography
Time consumption 45 min (Clinical history, physical exam, ECG evaluation, and
echo)
15 min
Table 4 Example of a database for evaluation and follow-up of cancer treatment cardiovascular complications
Baseline data
• General demographic and anthropometric data
• Contacts of general physician (GP) and other specialists following the patient
• Cardiovascular risk factors (previous and active, corrected or not)
• Cardiovascular illnesses prior to cancer treatment (coronary artery disease, valvular heart diseases, heart failure, and cardiac arrhythmias)
• Relevant general illnesses that may complicate cardiovascular and cancer treatment (e.g. moderate to severe kidney, hepatic, or lung diseases)
• Complete information about previous cancer therapies and eventual cardiotoxicities
Actual cancer disease
• Histology, site, tumor node metastasis staging (TNM), surgical treatment, and overall prognosis
• Complete information about ongoing cancer drugs (dosages and schedule)
• Complete information about planned radiotherapy (location, dosages, and schedules)
CV monitoring of cancer treatment
• Clinical baseline evaluation
• Baseline ECG and echocardiography if indicated in local clinical protocols
• Follow-up visits and diagnostic tests during cancer treatment
• Automatic recall to remember the planned visits/tests
• Estimate risk of possible long-term cardiotoxicity
Cancer therapy induced adverse events
• Cardiac events: heart failure, hypertension, cardiac arrhythmias, and vascular events
• Specific cardiac treatment
• Reversibility of cardiotoxicity
Periodic automatic recall of the patients and/or the GPs for updating clinical data















































..Feedback from referring allied members should be collected to
further develop the C-O Service and adapt to accommodate new pa-
tient groups when new cardiotoxic cancer therapies become
licenced. Governance meetings also allow new initiatives to be dis-
cussed and implemented, including involvement in C-O networks,
conferences, education and training, research studies, and registries.
Cancer survivorship program
The range of health problems faced by cancer survivors relating to
their disease and treatment is broad, and many oncology centres
now offer cancer survivorship programs. One essential issue of C-O
is to assure a safe long-term survival without the development of a
CV disease after defeating a cancer.9,16 Every patient judged at risk
for developing new CV disease should enter in a C-O follow-up pro-
gram. To achieve a good compliance to this program, patients should
be informed about potential risks and consequences of cardiotoxic-
ity, which might be significantly reduced applying tight life-style meas-
ures, planned controls, and taking the assigned therapies.6,13 To
reinforce these messages, primary healthcare professionals should
actively be involved in the program and intervene whenever appro-
priate. Specific recommendations about diagnostic tests and timing
for long-term follow-up have been emphasized in the recent ESC
position paper on cancer treatments and CV toxicity.5
Training and education
Training opportunities for cardiologists, oncologists, haematologists,
GPs, and other healthcare professionals are important and should be
provided by leading C-O Services.15,18 In addition to attending C-O
ward rounds, clinics and MDT meetings, C-O training should aim to
provide an opportunity for cardiology trainees to attend dedicated
tumour committees and learn the nomenclature, treatment options,
and the latest decision-making in modern oncology units. Vice versa,
oncology trainees wishing to train in C-O should attend cardiology
training opportunities in heart failure, cardiac imaging, and cardiac
interventions. Coordination with national training programmes to de-
velop a C-O curriculum is required. Specialist nurse training courses
and masters for both cardiology and oncology nurses is desirable to
develop the new generation of specialized C-O nurses. Larger C-O
Services as well as national and international societies should offer
dedicated C-O congresses or symposiums. In the next future, a
course within the ESC might be envisaged.
Also, the patients should receive proper education about C-O
issues in order to (i) improve the patient’s understanding of their dis-
ease, (ii) motivate them for prescribed medication adherence, and
(iii) help them to promptly identify and report the symptoms and
signs indicating progression of any CV disease. Meetings and confer-
ences could be organized during hospital stay, considering the help of
trained nurses or personnel. Booklets and dedicated informative
materials will be designed and validated across the C-O network.
Similar to other chronic conditions however, it will be essential to do
periodic recall and refreshments of the C-O issues.
Registries and clinical trials
Research is an important pillar of modern C-O to help develop the
scientific evidence upon which to base clinical decision-making. C-O
Services should engage in local, regional, national, and international
networks to collect data in registries such as the EuroObservational
Research Program C-O registry for breast cancer patients receiving
trastuzumab, and research networks to deliver clinical trials.19,20 A
common database might be set up among the various C-O Services.
....................................................................................................................................................................................................................
Table 5 Obstacles in implementing Cardio-Oncology Services
Obstacles Improvement measures
Cardio-Oncology Services not
adapted to cancer patients
numbers
• Consensus between cardiologists and oncologists to agree on local clinical protocols adapted to avail-
able resources and cancer treatment scheme
• C-O consultation time should be balanced with the requirement of every specific situation
• Case nurse manager
• Coordination with reference centres, family doctors, and specialized nurses to improve patients’
outcomes
Lack of professional training on
multidisciplinary team work
• Implementation of C-O services needs a good team selection of professionals, based on scientific
knowledge and on the ability to communicate and obtain consensus in difficult decisions
• Continuing medical education
Absence of C-O service standards
(Organization and specific roles
of the C-O Services, patients’
pathways, communication
tools, etc.)
• Define organization and specific roles of a C-O team and needs and referral for CO clinics
• Continuing medical education, research, and innovation
• Prospective database with clinical indicators and therapeutic strategies to clarify how and why final deci-
sions were reached and outcomes
• Health care quality control for clinical and research practice
Lack of funding • Cardio-oncology Services need to be adequately resourced and supported by institutional recognition
and opportunities for career development
• Facilities: administrative support (to schedule patients’ visits and tests; to document activities generated

























































































Another essential issue of large C-O Services is to increase the role
of cardio-oncologists in the follow-up of patients included in oncol-
ogy trials.
Funding and organizational issues
Common obstacles identifiable in the implementation of C-O
Services are related to the following: (i) the dedicated staff nature, (ii)
the lack of MDT training, (iii) the absence of organization manuals,
and (iv) the lack of funding (Table 5).
While the strategy of C-O Service seems to be cost-effective, it is
time and resources consuming (professional time, cardiac imaging
techniques, laboratory resources, etc.). Recognition by National and
European Health Authorities with appropriate funding and also legis-
lative identification is essential to permit appropriate resource alloca-
tion for C-O Services. Cardiology and oncology scientific societies
play an essential role, providing scientific evidences, epidemiologic
data, and population forecast to support this recognition requirement.
Knowledge translation and future
outlook
Cardio-Oncology practice requires complex organization that impacts
overall outcomes of cancer patients. Actually it may differ substantially
among hospitals and communities. The aim of this document is to de-
fine basic goals of C-O Services to optimize the existing ones and to
help the organization and implementation of C-O practice.
In the near future, C-O will be able to facilitate the transfer of re-
search evidence into clinical practice and policy development. Several
ways will be used to promote knowledge translation through the C-
O network (e.g. dedicated ESC Cardio-Oncology Council, website
with teaching courses, specific guidelines, scientific papers, results of
registries, or prospective studies).
Conclusion
There is an increasing awareness and clinical interest in cardiac safety
during cancer therapy as well as in optimally addressing cardiac issues
in cancer survivors. Multidisciplinary C-O programs have recently
been organized in dedicated C-O Services to diagnose and prevent
cardiotoxicity and to improve cancer patient care, well-being, and
long-term outcomes. Whilst many cardiology departments still do
not have a dedicated C-O Clinic, C-O is likely to become an increas-
ingly relevant sub-speciality. Every large hospital should have C-O
facilities. Small community hospitals should also have a C-O Team
with the possibility to follow and address at least the main cardiac
issues related to oncology treatment of cancer patients. The long-
term follow-up is an essential issue in this setting and requires a large,
well-organized network among the different actors in charge of can-
cer patients’ care.
Conflict of interest: none declared.
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